Cargando…

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales:	Synnott, Patricia G., McQueen, R. Brett, Ollendorf, Daniel A., Campbell, Jonathan D., Pearson, Steven D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Perspectives on Value
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390898/ https://www.ncbi.nlm.nih.gov/pubmed/32463783 http://dx.doi.org/10.18553/jmcp.2020.26.6.782

Ejemplares similares

Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2023)

The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Lancaster, Victoria, et al.
Publicado: (2022)

The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023)

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022)

The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022)

The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Fazioli, Katherine T., et al.
Publicado: (2020)

Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: McKenna, Avery, et al.
Publicado: (2023)

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Synnott, Patricia G, et al.
Publicado: (2021)

The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Pandey, Rajshree, et al.
Publicado: (2021)

Federal Advisory Councils Established to Assist Working Caregiving Families
por: Gibson, Ethlyn McQueen
Publicado: (2020)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of novel treatments for cystic fibrosis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2023)

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A., et al.
Publicado: (2020)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023)

Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults
por: Braeckman, Rene A., et al.
Publicado: (2014)

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects
por: Braeckman, Rene A, et al.
Publicado: (2015)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
por: Hilleman, Daniel E., et al.
Publicado: (2014)

Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f3jtf7sss594s88ld4onlpo687